Fig. 7
ANGPTL4 is associated with poor prognosis in TNBC patients. A Representative images (left) and quantification (right) of ANGPTL4, MKI67, ECAD, CD86 and CD206 expression in TNBC specimens with high or low D-2HG levels. Scale bar: 50 μm. B Box and whisker plot of ANGPTL4 expression according to basal-like and TNBC status from the Breast Cancer Gene-Expression Miner (bc-GenExMiner) database. C Violin plot (left) and scatter plot (right) of ANGPTL4 levels in the serum of healthy controls or BRCA patients from the Qilu cohort. D Violin plot (left) and scatter plot (right) of ANGPTL4 mRNA levels in BRCA tumor tissues versus normal tissues from the Qilu cohort. E Heatmaps showing the correlations between ANGPTL4 expression and overall survival (OS) as well as disease-free survival (DFS), based on the hazard ratio (HR) from different molecular subtype classification methods in bc-GenExMiner. F Survival curves of basal-like patients according to Hu’s breast cancer classification method in bc-GenExMiner for the correlations between ANGPTL4 expression and OS as well as DFS. G Schematic diagram underlying the roles of D-2HG-mediated m6A-dependent ANGPTL4 secretion in TNBC, which facilitates tumor progression by regulating tumor cell proliferation and metastasis (via autocrine signaling), as well as enhancing tumor-promoting M2 macrophage infiltration (via paracrine signaling). *P < 0.05, **P < 0.01, ***P < 0.001